Publication: Observational Cohort Study of the Safety of Digoxin Use in Women with Heart Failure
Open/View Files
Date
2012
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
BMJ Group
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Flory, James H., Bonnie Ky, Kevin Haynes, Steve M. Brunelli, Jeffrey Munson, Christopher Rowan, Brian L Strom, and Sean Hennessy. 2012. Observational cohort study of the safety of digoxin use in women with heart failure. BMJ Open 2(2): e000888.
Research Data
Abstract
Objectives: This study aims to assess whether digoxin has a different effect on mortality risk for women than it does for men in patients with heart failure (HF). Design This study uses the UK-based The Health Information Network population database in a cohort study of the impact of digoxin exposure on mortality for men and women who carry the diagnosis of HF. Digoxin exposure was assessed based on prescribing data. Multivariable Cox proportional hazards models were used to assess whether there was an interaction between sex and digoxin affecting mortality hazard. Setting The setting was primary care outpatient practices. Participants The study cohort consisted of 17 707 men and 19 227 women with the diagnosis of HF who contributed only time without digoxin exposure and 9487 men and 10 808 women with the diagnosis of HF who contributed time with digoxin exposure. Main outcome measures The main outcome measure was all-cause mortality. Results: The primary outcome of this study was the absence of a large interaction between digoxin use and sex affecting mortality. For men, digoxin use was associated with a HR for mortality of 1.00, while for women, the HR was also 1.00 (p value for interaction 0.65). The results of sensitivity analyses were consistent with those of the primary analysis. Conclusion: Observational data do not support the concern that there is a substantial increased risk of mortality due to the use of digoxin in women. This finding is consistent with previous observational studies but discordant with results from a post hoc analysis of a randomised controlled trial of digoxin versus placebo.
Description
Other Available Sources
Keywords
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service